Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-50717 (deutetrabenazine) for Tourette syndrome in children and adolescents
2016-000622-19Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tourette syndrome (TS) comparing Deutetrabenazine with Placebo (2 arms). Primary endpoint: Change in Total Tic Score of YGTSS from baseline to week 12. Started Feb 2018; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2016-000622-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000622-19.